CAR T cell therapy reaches beyond cancer

PHILADELPHIA— Engineered immune cells, known as CAR T cells, have shown the world what personalized immunotherapies can do to fight blood cancers. Now, investigators have reported highly promising ... Read More

Penn Medicine developed CAR T cell therapy wins third FDA approval

PHILADELPHIA – The U.S. Food and Drug Administration (FDA) has expanded its approval for a personalized cellular therapy developed at the University of Pennsylvania’s Abramson Cancer Center, this time ... Read More

Penn Medicine leads cancer treatment breakthroughs in CAR T-cell therapy

Penn Medicine is advancing cancer treatment with its work in CAR T-cell therapy, an innovative immunotherapy that is reshaping the fight against blood cancers and rare genetic diseases. Penn Medicine ... Read More

FDA is investigating whether CAR-T, a cancer therapy pioneered at Penn, can cause lymphoma

University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug Administration announced Tuesday an investigation into whether the ... Read More

Enhanced CAR T cell therapy offers new strategy for lymphoma

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ... Read More

Radiation doesn't disrupt cellular cancer therapy, Penn study finds

Multiple myeloma patients can safely receive radiation therapy while they wait for an infusion of CAR-T cells – a cancer treatment that trains a patient's immune cells to track down and kill cancerous ... Read More

Next-generation "armored" CAR T cell therapy shows promising results in lymphoma patients

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ... Read More

Penn Medicine and CHOP partner with Costa Rica to advance breakthrough cancer therapy

Penn Medicine and Children’s Hospital of Philadelphia have partnered with Costa Rica’s social security program to advance CAR T-cell cancer therapy research, a type of immunotherapy that could improve ... Read More

CAR T cell therapy targeting HER2 antigen shows promise against advanced sarcoma in phase I trial

Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist published results of a phase I ... Read More

Penn Medicine, CHOP enter into partnership to bring CAR T-cell therapy to Costa Rica

CHOP and Penn Medicine each signed a memorandum of understanding with the Costa Rica social security program in a ceremony attended by First Lady Jill Biden. CEO of ... Read More

CAR T cell therapy reaches beyond cancer

Investigators have reported highly promising early results for CAR T therapy in a small set of patients with the autoimmune disease lupus. Engineered immune cells, known as CAR T cells, have shown the ... Read More